Business
COCRYSTAL PHARMA, INC. PRICES $2.2 MILLION REGISTERED DIRECT OFFERING
BOTHELL, WA, Jan. 29, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company
About this update from Cocrystal Pharma, Inc.
[{"type":"text","content":"BOTHELL, WA, Jan. 29, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced the pricing of a registered direct offering with gross proceeds to the Company expected to be approximately $2.2 million before deducting placement agent commissions and expenses. The proposed offering equates to 3,492,063 shares of common stock at $0.63 per share. The Company intends to use the net proceeds for working capital and other general corporate purposes.\n The offering is expected to close on or about January 31, 2020, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as sole placement agent for the offering. This offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-220632) previously filed with the SEC. A prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC. Once filed, electronic copies of the preliminary prospectus supplement may be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 36th Floor, New York, NY 10022 or via telephone at 212-624-2060 or email: [email protected]. Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that Cocrystal has filed and will file with the SEC or that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about Cocrystal and the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Cocrystal Pharma, Inc. Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. Forward-Looking StatementsThis press release contains forward-looking statements wit...